Navigation Links
Generex Announces Scheduling of USFDA End-of-Phase II Meeting for the AE37 Breast Cancer Vaccine
Date:6/7/2012

WORCESTER, Mass. and TORONTO, June 7, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) announced today that an End-of-Phase II meeting has been scheduled with the United States Food and Drug Administration (FDA) in respect of the Phase II clinical trial of the AE37 breast cancer vaccine being undertaken by its wholly-owned subsidiary, Antigen Express, Inc.

The meeting has been scheduled for June 18, 2012 with FDA regulatory management staff in the Office of Cellular Tissues and Gene Therapies in the Center for Biologics Evaluation and Research.  Antigen Express has provided the FDA with a comprehensive and detailed package regarding the AE37 breast cancer vaccine, the on-going Phase II clinical trial, and the company's plans for a transition into a pivotal Phase III trial.

Antigen Express will solicit guidance from the FDA regarding the company's proposed structure of a pivotal Phase III trial.

In addition to representatives of Antigen Express, Dr. Samuel Jacobs, MD, Director, Medical Affairs, National Surgical Adjuvant Breast and Bowel Project (NSABP) and a member of the Antigen Express AE37 breast cancer Scientific Advisory Board (SAB), will attend the meeting to proffer his advice and assistance on behalf of Antigen Express.  The NSABP is a clinical trials cooperative group supported since its inception by the National Cancer Institute (NCI). It has a more than 50-year history of designing and conducting clinical trials that have changed the way breast cancer is treated, and, more recently, prevented.  The NSABP was the first to demonstrate that adjuvant therapy could alter the natural history of breast cancer.  Since its inception, the NSABP has enrolled more than 110,000 women and men in clinical trials in breast and colorectal cancer.  It has research sites at nearly 1000 major medical centers, university hospitals, large oncol
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
2. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
3. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
4. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
5. Generex Secures Commitments for $3.6M Capital Raise
6. Generex Announces Patent Award for its Core Vaccine Technologies in Japan
7. Generex Subsidiary Antigen Express Announces Press Conference at American Association for Cancer Research Related to the Immunological Response of its AE37 Vaccine to Prevent Recurrence of Breast Cancer
8. Generex Announces Date of Annual Stockholders Meeting
9. Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers
10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
11. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... people over 60 are not donor candidates for bone ... time, making the elderly prone to life-threatening infection and ... now has discovered a reason why. , "We have ... blood-forming cells to maintain blood production over time in ... could be restored for rejuvenation therapies," said Emmanuelle Passegu, ...
(Date:7/31/2014)... 2014 The SNIS Foundation recognized its ... fund a translational research project.  The first award ... was presented at the Society of NeuroInterventional Surgery ... Colorado Springs, CO. ... neurovascular conditions, SNIS formed the SNIS Foundation, in ...
(Date:7/31/2014)... 31, 2014 According to a ... for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, ... TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global ... - 2019," the global electrodes market for medical devices ... is estimated to reach a market worth USD 1,451.2 ...
(Date:7/31/2014)... SHENZHEN, China , July 31, 2014 /PRNewswire/ ... of an Irys™System by BGI , ... to enable comprehensive exploration of human structural variation (SV) ... of interest, including those where no reference exists. In ... new methods for multiplexing on the Irys System, enabling ...
Breaking Biology Technology:Key to aging immune system is discovered 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4
... June 3 /PRNewswire-FirstCall/ - YM BioSciences Inc.,(AMEX: ... company that identifies,develops and commercializes differentiated products for ... clinical trials of its,anti-cancer drug nimotuzumab, a humanized ... were presented at the 2008 American,Society of Clinical ...
... 3 ViroPharma Incorporated,(Nasdaq: VPHM ) today ... of ViroPharma, will present at the Goldman Sachs ... on Tuesday, June 10,2008. The conference is being ... CA., ViroPharma also announced that William Roberts, ...
... FRANCISCO, Calif., June 3 Exelixis,Inc. (Nasdaq: EXEL ... chief executive officer of Exelixis, will present at the ... PT/2:00 p.m. ET on,Tuesday, June 10, 2008. Dr. Scangos ... strategy., The presentation will be webcast and may ...
Cached Biology Technology:NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING 2NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING 3NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING 4ViroPharma to Present at Two Upcoming Healthcare Conferences 2
(Date:7/31/2014)... tracing nearly 3,000 genes to the earliest common ... scientists have created an extensive "Tree of Lepidoptera" ... DNA sequencing. , Among the study,s more ... small moths than to large ones, which completely ... study also found that some insects once classified ...
(Date:7/31/2014)... Researchers who studied 100 twin pairs have identified a ... on less than six hours of sleep per night. ... the effects of sleep deprivation. , Results show that a ... had an average nightly sleep duration of only five ... non-carrier twin, who slept for about six hours and five ...
(Date:7/31/2014)... researchers have completed a 20-year study that looks ... at different times of the year. It finds ... time frame has no measurable negative consequences for ... benefits. , The study was conducted by Gene ... Station fire chief, and Joseph Craine, research assistant ...
Breaking Biology News(10 mins):UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3Study of twins discovers gene mutation linked to short sleep duration 2Study finds benefits to burning Flint Hills prairie in fall and winter 2Study finds benefits to burning Flint Hills prairie in fall and winter 3
... Researchers used blood platelets and bone marrow cells ... of the human genetic disorder Hurler syndrome an ... medical complications. Scientists from Cincinnati Children,s Hospital Medical ... Stroke (NINDS) report their unique strategy for treating the ...
... 4, 2014) A new study by George Washington ... in the pathogenesis of prion disease misfolded proteins ... HIV virus. The research, published in the ... relationship between cholesterol metabolism and prion infection as a ...
... expected to decrease fitness, new research, published in Respirology ... motivation and are more likely to suffer symptoms of anxiety ... from Universidade Estadual de Londrina, Brazil, is the first study ... 60 smokers and 50 non-smokers were asked to wear ...
Cached Biology News:Mouse study shows gene therapy may be possible cure for Hurler syndrome 2GW researcher finds connection in pathogenesis of neurological diseases, HIV 2
... glutathione-S-transferase (GST) is commonly used as a ... coli (1). The GSTTag sequence has been ... some cases the solubility of its fusion ... folded form, GSTTag fusion proteins can be ...
... the next step in the evolution of ... system that delivers labware to multiple laboratory ... times the throughput of ordinary microplate robots. ... variety of configurations to meet any labs ...
... the use of small interfering RNA (siRNA) ... RNA interference (RNAi) pathway have generated tremendous ... fields. siRNA for experimental use can be ... and then transfected into the target cells ...
... The S&S Custom Array Service enables scientists ... analysis instrumentation to have FAST Slides printed with ... own library. Processing of the arrays is performed ... Contact S&S to discuss your needs with ...
Biology Products: